Phil Vickers is President and CEO of Solu Therapeutics, a Boston clinical-stage biotech building small-molecule 'chimeras' that ferry cytotoxic payloads to disease-driving cells. He arrived in September 2023 after runs at Faze Medicines and Northern Biologics, and R&D leadership at Shire, Boehringer-Ingelheim, Pfizer and Merck. In April 2025 he closed a $41M Series A with Eli Lilly, Pappas Capital and the Leukemia & Lymphoma Society and dosed the first patient in a Phase 1 trial of STX-0712 for CMML.
Solu Therapeutics is a Boston-based clinical-stage biotech building a new class of medicines that selectively kill disease-driving cells. Its proprietary CyTAC (Cytotoxicity Targeting Chimera) and TicTAC (Therapeutic Index Control Targeting Chimera) platforms fuse the precise binding of small molecules with the cell-killing power of antibodies, reaching cell-surface targets - like GPCRs and ion channels - that traditional antibodies cannot. Its lead program, STX-0712, is a CCR2-targeting candidate in a Phase 1 trial for chronic myelomonocytic leukemia and other advanced blood cancers.